Postoperative Analgesia in Patients Undergoing Open Upper Abdominal Surgeries: External Ob
Open upper abdominal surgeries with subcostal incisions are a cause of severe pain and can lead to pulmonary and cardiac complications, detrimental physiological effects, and may also have psychological, economic, and social adverse effects if inadequately treated. Effective pain control can avoid these complications a
| Condition(s) | Post Operative Pain |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Open upper abdominal surgeries with subcostal incisions are a cause of severe pain and can lead to pulmonary and cardiac complications, detrimental physiological effects, and may also have psychological, economic, and social adverse effects if inadequately treated. Effective pain control can avoid these complications and contribute to several clinically valuable outcomes, including earlier patient mobilization and quicker recovery, which can result in a shortened hospital stay and reduced costs. Opioids are the gold standard in postoperative pain control. however, it increases the incidence of opioid related adverse events such as respiratory depression, dizziness, nausea, vomiting and constipation. Regional analgesia plays an important role in perioperative multimodal analgesic regimens f |
| Who can participate | Inclusion Criteria: * Patients from both sexes. * 18 to 60 years old. * ASA physical status I- III scheduled for elective open upper abdominal surgeries, as (open nephrectomy, open cholecystectomy, liver resection, ….). * Patients with BMI (18.5-35) kg/ m2. Exclusion Criteria: * Patients uncooperative or refuse to sign the consent of regional block. * Patients with known coagulation defects. International normalized ratio (INR)\> 1.5), and thrombocytopenia if platelet count \< 100.000). * Patients with known hypersensitivity to bupivacaine, or any of the used drugs. * Patients with hepatic impairment, as Child-Pugh class B or C, AST/ALT \> 3 times the upper limit of normal, or total bilirubin \> 2 mg/dL. * Patients with renal impairment, chronic kidney disease stage 4 or 5 (eGFR \< 30 mL/m |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Lead sponsor | Cairo University |
| Locations | Cairo, Egypt |
| Start date | 2025-08-15 |
| NCT ID | NCT07094386 |
| Official listing | https://clinicaltrials.gov/study/NCT07094386 |